Date of the CVA	07/01/2021

Section A. PERSONAL DATA

Name and Surname	Isabel Merida de San Roman		
DNI/NIE/Passport		Age	
Researcher's identification number	Researcher ID		
	Scopus Author ID		
	ORCID	0000-0003-2762-6241	

* Obligatorio

A.1. Current professional situation

Institution	Centro Nacional de Biotecnología		
Dpt. / Centre			
Address			
Phone		Email	
Professional category	Profesora Investigación	Start date	2007
Keywords			

A.2. Academic education (Degrees, institutions, dates)

Bachelor/Master/PhD	University	Year
Doctora en Ciencias Quimicas	Universidad Complutense de Madrid	1987
Licenciado en Ciencias Químicas Especialidad Bioquímica	Universida Complutense de Madrid	1981

A.3. General quality indicators of scientific production

Scopus author:700391338
WOS Researcher ID: A-9713-2014
Five six-years periods of recognized excellence in research
Number of supervised doctoral thesis : 18, four in progress
(WOS) H-index : 38. Total number of citations : 4232
(SCOPUS) H-index: 38
Period 2016-2020. Total publications 17. Total Cites1104.

Section B. SUMMARY OF THE CURRICULUM

Dr Merida has a Chemistry Bsc (1984) and a PhD in Biochemistry (1987) from the Universidad Complutense de Madrid. She trained as a researcher in the United States working at the Medical School in UMASS and in the Division of Immunology at the University of Pennsylvania as a Leukemia Society Fellow. In 1992 she returned to Spain where she joined the National Center for Biotechnology (CNB) as a Junior Spanish Research Council (CSIC) scientist. In 2003 she was appointed senior CSIC researcher and Professor in 2008, Dr Merida's team study the mechanisms that regulate T lymphocyte actions. Their work has helped to identify Diacylglcyerol Kinases as negative regulators of immune responses. In collaboration with other academic groups and pharmaceutical companies, Dr Merida's team works to learn how to manipulate these enzymes to fight cancer. Dr. Merida is co-author of over 80 scientific publications, has supervised 14 Ph.D, Thesis and several Master Thesis. Her laboratory hosts postdoctoral scientists and students from several nationalities and obtains competitive funding from national and international agencies. Dr. Merida participates regularly in reviewer tasks for Spanish, European and American funding agencies and international journals. From 2006 until 2011 Dr Merida was appointed as member of the Biology and Biomedicine Committee at the CSIC, where she participated in the organization of the first strategic scientific plan for this Area. From 2012 to 2014 she was appointed member of the National Commission for Evaluation of Scientific Activity in the area of Biomedicine. From 2007 until 2016 she has acted as Vicedirector of the CNB.

Section C. MOST RELEVANT MERITS (ordered by typology)

C.1. Publications

AC: Autor de correspondencia; (nº x / nº y): posición firma solicitante / total autores

1 **Scientific paper**. Arranz-Nicolas, Javier; Martin-Salgado, Miguel; Rodriguez-Rodriguez, Cristina; et al; Merida, Isabel. 2020. Diacylglycerol kinase zeta limits IL-2-dependent control of PD-1 expression in tumor-infiltrating T lymphocytes JOURNAL FOR IMMUNOTHERAPY OF CANCER. 8-2.

2 **Scientific paper**. Merino-Cortes, Sara V.; Gardeta, Sofia R.; Roman-Garcia, Sara; et al; Carrasco, Yolanda R.2020. Diacylglycerol kinase zeta promotes actin cytoskeleton remodeling and mechanical forces at the B cell immune synapse SCIENCE SIGNALING. 13-627. ISSN 1945-0877.

3 **Scientific paper**. Arranz-Nicolas, Javier; Ogando, Jesus; Soutar, Denise; Arcos-Perez, Raquel; Meraviglia-Crivelli, Daniel; Manes, Santos; Merida, Isabel; Avila-Flores, Antonia. 2018. Diacylglycerol kinase alpha inactivation is an integral component of the costimulatory pathway that amplifies TCR signals CANCER IMMUNOLOGY IMMUNOTHERAPY. 67-6, pp.965-980. ISSN 0340-7004.

4 **Scientific paper**. Tello-Lafoz, M.; Rodriguez-Rodriguez, C.; Kinna, G.; Loo, L. S.; Hong, W.; Collins, B. M.; Teasdale, R. D.; Merida, I.2017. SNX27 links DGK zeta to the control of transcriptional and metabolic programs in T lymphocytes SCIENTIFIC REPORTS. 7. ISSN 2045-2322.

5 **Scientific paper**. Tello-Lafoz, Maria; Martinez-Martinez, Gonzalo; Rodriguez-Rodriguez, Cristina; Albar, Juan Pablo; Huse, Morgan; Gharbi, Severine; Merida, Isabel. 2017. Sorting nexin 27 interactome in T-lymphocytes identifies zona occludens-2 dynamic redistribution at the immune synapse TRAFFIC. 18-8, pp.491-504. ISSN 1398-9219.

6 **Scientific paper**. Andrada, Elena; Liebana, Rosa; Merida, Isabel. 2017. Diacylglycerol Kinase zeta Limits Cytokine-dependent Expansion of CD8(+) T Cells with Broad Antitumor Capacity EBIOMEDICINE. 19, pp.39-48. ISSN 2352-3964.

7 **Scientific paper**. Isabel Mérida; Antonia Avila-Flores; Javier Arranz-Nicolás; Elena Andrada; Denise Soutar. 2017. Predominant contribution of DGKζ over DGKα in the control of PKC/PDK-1-regulated functions in T cells.Immuno Cell Biol. WILEY. Jul;95-6, pp.549-563.

8 **Scientific paper**. Tello-Lafoz M; Rodriguez-Rodriguez C; Kinna G; Loo LS; Hong W; Collins BM; Mérida I. 2017. SNX27 links DGKζ to the control of transcriptional and metabolic programs in T lymphocytes Sci Rep. Springer Nature. Nov 27;7-1, pp.16361.

9 **Scientific paper**. 2016. Diacylglycerol kinase ζ limits the polarized recruitment of diacylglycerol-enriched organelles to the immune synapse in T cells.Sci Signal.Dec 20; 9-(459), pp.ra127..

10 **Scientific paper**. 2016. A molecular code for endosomal recycling of phosphorylated cargos by the SNX27–retromer complex Nat Struct Mol Biol.Oct;23-(10), pp.921-932.

11 **Scientific paper**. Torres-Ayuso, P.; Tello-Lafoz, M.; Merida, I.; Avila-Flores, A.2015. Diacylglycerol kinase-zeta regulates mTORC1 and lipogenic metabolism in cancer cells through SREBP-1 ONCOGENESIS. 4. ISSN 2157-9024.

12 **Scientific paper**. 2015. Phosphoinositide binding by the SNX27 FERM domain regulates its localization at the immune synapse of activated T-cells.J Cell Sci.Feb 1;128-(3), pp.553-565.

13 **Scientific paper**. Torres Ayuso, P.; Tello Lafoz, M.; Mérida, I.; Ávila Flores, A.2015. Diacylglycerol kinase-? regulates mTORC1 and lipogenic metabolism in cancer cells through SREBP-1.Oncogenesis. 4, pp.e164. ISSN 2157-9024.

14 **Review**. Gonzalez-Mancha, Natalia; Merida, Isabel. 2020. Interplay Between SNX27 and DAG Metabolism in the Control of Trafficking and Signaling at the IS INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 21-12.

15 **Review**. Arranz-Nicolas, Javier; Merida, Isabel. 2020. Biological regulation of diacylglycerol kinases in normal and neoplastic tissues: New opportunities for cancer immunotherapy.Advances in biological regulation. 75, pp.100663-100663.

16 **Review**. Merida, Isabel; Arranz-Nicolas, Javier; Torres-Ayuso, Pedro; Avila-Flores, Antonia. 2020. Diacylglycerol Kinase Malfunction in Human Disease and the Search for Specific Inhibitors.Handbook of experimental pharmacology. 259, pp.133-162. ISSN 0171-2004.

17 **Review**. Merida, Isabel; Arranz-Nicolas, Javier; Rodriguez-Rodriguez, Cristina; Avila-Flores, Antonia. 2019. Diacylglycerol kinase control of protein kinase C BIOCHEMICAL JOURNAL. 476, pp.1205-1219. ISSN 0264-6021.

18 **Review**. Merida I; Torres-Ayuso P; Avila-Flores A; Arranz-Nicolás J; Andrada E; Tello-Lafoz M; Liébana R; Arcos R. 2017. Diacylglycerol kinases in cancer Adv Biol Regul.ELSEVIER. Jan;63, pp.22-31.

19 **Review**. 2015. Redundant and specialized roles for diacylglycerol kinases α and ζ in the control of T cell functions.Sci Signal.Apr 28;8-(374), pp.re6.

C.2. Participation in R&D and Innovation projects

1 Diacylglycerol Kinase inhibitors for cancer immunotherapy Ministerio de Ciencia e Innovación. Isabel Merida. (Centro Nacional de Biotecnología). 01/09/2020-31/08/2023. 200.000 €.

2 Tumoral immunity and cancer immunotherapy Consejería de Sanidad de la Comunidad de Madrid. Santos Mañes. (Centro Nacional de Biotecnología). 01/12/2017-01/12/2021. 991,2 €.

3 Diacylglycerol kinases as new targets for immunotherapy treatment in pediatric brain tumors Asociación Española Contra el Cáncer. (Centro Nacional de Biotecnología). 01/10/2018-30/09/2021. 300.000 €.

4 Diacylglycerol kinase deficiency triggers early signs of aplastic anemia in mice. Aplastic Anemia and Myelodisplasia International Foundation. Isabel Merida. (Centro Nacional de Biotecnología). 01/06/2018-31/05/2021. 60.000 €.

5 El metabolismo del diacilglicerol en la regulación de la tolerancia de las células T y la evasión de tumores Ministerio de Economia y Competitividad. (Centro Nacional de Biotecnología). 01/01/2014-31/12/2016. 250.000 €.

C.3. Participation in R&D and Innovation contracts

GSK Fast Track 01/01/2016-01/04/2017.

C.4. Patents